Literature DB >> 31677319

Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria After Thermal Ablation for Hepatocellular Carcinoma.

Katherine S Cools1, Andrew M Moon2, Lauren M B Burke3, Katrina A McGinty3, Paula D Strassle1,4, David A Gerber1,5.   

Abstract

Single hepatocellular carcinoma (HCC) tumors can be successfully eradicated with thermal ablation (TA). We assessed the validity of the Liver Imaging Reporting and Data System Treatment Response (LR-TR) criteria with a retrospective analysis of a single-center database of patients with small HCC tumors (<3 cm in diameter) who underwent both laparoscopic TA and liver transplantation (LT) from 2004 to 2018. Postablation MRIs were assigned LR-TR categories (nonviable, equivocal, and viable) for ablated lesions and Liver Imaging Reporting and Data System (LI-RADS) categories (probable or definite HCC) for untreated lesions. Interpretations were compared with the histopathology of the post-LT explanted liver. There were 45 patients with 81 tumors (59 ablated and 22 untreated; mean size, 2.2 cm), and 23 (39%) of the ablated tumors had viable HCC on histopathology. The sensitivity/specificity of LR-TR categories (nonviable/equivocal versus viable) of ablated tumors was 30%/99%, with a positive predictive value (PPV)/negative predictive value (NPV) of 93%/69%. The sensitivity varied with residual tumor size. The sensitivity/specificity of LI-RADS 4 and 5 diagnostic criteria at detecting new HCC was 65%/94%, respectively, with a PPV/NPV of 85%/84%. The interrater reliability (IRR) was high for LR-TR categories (90% agreement, Cohen's ĸ = 0.75) and for LI-RADS LR-4 and LR-5 diagnostic categories (91% agreement, Cohen's ĸ = 0.80). In patients with HCC <3 cm in diameter, LR-TR criteria after TA had high IRR but low sensitivity, suggesting that the LR-TR categories are precise but inaccurate. The low sensitivity may be secondary to TA's disruption in the local blood flow of the tissue, which could affect the arterial enhancement phase on MRI. Additional investigation and new technologies may be necessary to improve imaging after ablation.
Copyright © 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2019        PMID: 31677319      PMCID: PMC6980979          DOI: 10.1002/lt.25673

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  48 in total

Review 1.  Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques.

Authors:  Jordi Bruix; Maria Reig; Jordi Rimola; Alejandro Forner; Marta Burrel; Ramón Vilana; Carmen Ayuso
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

2.  Does a combined CT and MRI protocol enhance the diagnostic efficacy of LI-RADS in the categorization of hepatic observations? A prospective comparative study.

Authors:  Mohammad Abd Alkhalik Basha; Mohamad Zakarya AlAzzazy; Ayman F Ahmed; Hala Y Yousef; Samar Mohamad Shehata; Dena Abd El Aziz El Sammak; Talaat Fathy; Ahmed Ali Obaya; Eman H Abdelbary
Journal:  Eur Radiol       Date:  2018-01-24       Impact factor: 5.315

3.  Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria.

Authors:  Chikako Suzuki; Michael R Torkzad; Hans Jacobsson; Gunnar Aström; Anders Sundin; Thomas Hatschek; Hirofumi Fujii; Lennart Blomqvist
Journal:  Acta Oncol       Date:  2010-05       Impact factor: 4.089

Review 4.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

5.  Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma.

Authors:  Thomas Decaens; Françoise Roudot-Thoraval; Solange Bresson-Hadni; Carole Meyer; Jean Gugenheim; Francois Durand; Pierre-Henri Bernard; Olivier Boillot; Karim Boudjema; Yvon Calmus; Jean Hardwigsen; Christian Ducerf; Georges Philippe Pageaux; Sebastien Dharancy; Olivier Chazouilleres; Daniel Dhumeaux; Daniel Cherqui; Christophe Duvoux
Journal:  Liver Transpl       Date:  2005-07       Impact factor: 5.799

6.  Radiology estimates of viable tumor percentage in hepatocellular carcinoma ablation cavities correlate poorly with pathology assessment.

Authors:  Joshua Anspach Hanson; Regina Ason; Jeffrey Weinreb; Alison Van Dyke; Kisha Anne Mitchell
Journal:  Arch Pathol Lab Med       Date:  2013-03       Impact factor: 5.534

7.  The new liver allocation system: moving toward evidence-based transplantation policy.

Authors:  Richard B Freeman; Russell H Wiesner; Ann Harper; Sue V McDiarmid; Jack Lake; Erick Edwards; Robert Merion; Robert Wolfe; Jeremiah Turcotte; Lewis Teperman
Journal:  Liver Transpl       Date:  2002-09       Impact factor: 5.799

8.  Liver Imaging Reporting and Data System v2014 With Gadoxetate Disodium-Enhanced Magnetic Resonance Imaging: Validation of LI-RADS Category 4 and 5 Criteria.

Authors:  Sang Hyun Choi; Jae Ho Byun; So Yeon Kim; So Jung Lee; Hyung Jin Won; Yong Moon Shin; Pyo Nyun Kim
Journal:  Invest Radiol       Date:  2016-08       Impact factor: 6.016

9.  Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

Authors:  Alejandro Forner; Carmen Ayuso; María Varela; Jordi Rimola; Amelia J Hessheimer; Carlos Rodriguez de Lope; María Reig; Luís Bianchi; Josep M Llovet; Jordi Bruix
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

10.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

Authors:  V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 176.079

View more
  7 in total

Review 1.  Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma.

Authors:  Guilherme Moura Cunha; Victoria Chernyak; Kathryn J Fowler; Claude B Sirlin
Journal:  J Hepatocell Carcinoma       Date:  2021-05-31

2.  Application of the CT/MRI LI-RADS Treatment Response Algorithm to Contrast-Enhanced Ultrasound: A Feasibility Study.

Authors:  Si-Min Ruan; Mei-Qing Cheng; Hui Huang; Hang-Tong Hu; Wei Li; Xiao-Yan Xie; Ming-De Lu; Ming Kuang; Man-Xia Lin; Wei Wang
Journal:  J Hepatocell Carcinoma       Date:  2022-05-20

Review 3.  LI-RADS treatment response assessment of combination locoregional therapy for HCC.

Authors:  Marielia Gerena; Christopher Molvar; Mark Masciocchi; Sadhna Nandwana; Carl Sabottke; Bradley Spieler; Rishi Sharma; Leo Tsai; Ania Kielar
Journal:  Abdom Radiol (NY)       Date:  2021-06-13

4.  LI-RADS treatment response algorithm for detecting incomplete necrosis in hepatocellular carcinoma after locoregional treatment: a systematic review and meta-analysis using individual patient data.

Authors:  Tae-Hyung Kim; Sungmin Woo; Ijin Joo; Mustafa R Bashir; Mi-Suk Park; Lauren M B Burke; Mishal Mendiratta-Lala; Richard K G Do
Journal:  Abdom Radiol (NY)       Date:  2021-05-23

Review 5.  Interreader Reliability of Liver Imaging Reporting and Data System Treatment Response: A Systematic Review and Meta-Analysis.

Authors:  Dong Wook Kim; Sang Hyun Choi; Ji Sung Lee; So Yeon Kim; So Jung Lee; Jae Ho Byun
Journal:  Diagnostics (Basel)       Date:  2021-02-04

6.  Performance of LI-RADS version 2018 CT treatment response algorithm in tumor response evaluation and survival prediction of patients with single hepatocellular carcinoma after radiofrequency ablation.

Authors:  Yun Zhang; Jinju Wang; Hui Li; Tianying Zheng; Hanyu Jiang; Mou Li; Bin Song
Journal:  Ann Transl Med       Date:  2020-03

Review 7.  Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions.

Authors:  Anum Aslam; Richard Kinh Gian Do; Avinash Kambadakone; Bradley Spieler; Frank H Miller; Ahmed M Gabr; Resmi A Charalel; Charles Y Kim; David C Madoff; Mishal Mendiratta-Lala
Journal:  World J Hepatol       Date:  2020-10-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.